Dr. Lau is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
160 E 34th St
Fl 8
New York, NY 10016Phone+1 212-404-3696
Education & Training
University of British ColumbiaClass of 2013
Certifications & Licensure
NY State Medical License 2021 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Daratumumab in STK11 Mutated NSCLC Start of enrollment: 2023 Jun 01
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 3 citationsCTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun
Nature. 2024-11-01 - 1 citationsTo Crush or Not to Crush: Administering Dabrafenib and Trametinib Through a Nasogastric Tube in a Critically Ill Patient With Nonsmall Cell Lung Cancer - A Case Report...Charley Jang, Sally Cm Lau, Vamsidhar Velcheti
Clinical Lung Cancer. 2024-05-01 - Top 20NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of ActivatingMutations in NSCLC. An Editor-in-Chief Expert Panel Con...Sai-Hong Ignatius Ou, Xiuning Le, Misako Nagasaka, Thanyanan Reungwetwattana, Myung-Ju Ahn
Lung Cancer. 2024-01-01
Press Mentions
Tarlatamab plus PD-L1 Inhibitor as Potential First-Line Maintenance for Extensive-Stage Small Cell Lung CancerOctober 8th, 2024- TKI plus Chemotherapy Prolonged Survival Outcomes in NSCLC with Brain MetastasesFebruary 22nd, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
